Citations

Clear

7552 citation(s) found for "Ho, Matthew".

Author response: Initial elevations in glutamate and dopamine neurotransmission decline with age, as does exploratory behavior, in LRRK2 G2019S knock-in mice
Paschall, Sarah A. , MacIsaac, Sarah E, Kuhlmann, Naila , Kadgien, Chelsie , Fox, Jesse D. , Khinda, Jaskaran, Mitchell, Emma , Bergeron, Sabrina , Melrose, Heather L. , Milnerwood, Austen J. , Volta, Mattia , Beccano-Kelly, Dayne , Cataldi, Stefano , Tatarnikov, Igor , Farrer, Matthew J.

Mayo Clinic

No container title available | October 9, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.28377.016 Get It

Incidence and predictors of osteoporotic fractures in patients with Barrett's oesophagus: a population‐based nested case‐control study
Kumar, Swarup , Schleck, C. D., Johnson, Michele L., Alexander, J.A., Katzka, David A. , Iyer, Prasad G. , Kumar, S , Iyer, P G , Drake, Matthew T. , Alexander, J. A.

Mayo Clinic

Alimentary Pharmacology & Therapeutics | October 5, 2017 | Volume: 46 | Issue: 11-12 | Pages: 1094-1102

10.1111/apt.14345 | PMID 28980336 Get It

SummaryBackgroundProton pump inhibitors (PPI) are inconsistently associated with osteoporotic fractures. Barrett's oesophagus (BO) patients are treated with high PPI doses for prolonged periods, but there are limited data on the incidence of osteoporosis and fractures in this group pf patients.AimTo estimate the incidence of (and risk factors for) low bone mass (osteoporosis and/or osteopenia) related fractures in a population‐based BO cohort.MethodsAll subjects with BO and a diagnosis of osteoporosis and fractures were identified using Rochester Epidemiology Project resources. The incidence rates of all and osteoporotic fractures in these subjects were compared to an age‐ and gender similar population in Olmsted County to determine standardised incidence ratios (SIR). Predictors were assessed using Cox proportional hazards models.ResultsFive hundred and twenty‐one patients were included (median [IQR] age 61 [52, 72] years; 398 [76%] men) of whom 113 (21.7%) had fractures, and 46 (8.8%) had osteoporotic fractures. The incidence of all fractures and osteoporotic fractures was comparable to that of an age‐ and gender‐matched population (SIR 1.09; 95% CI 0.92‐1.29: SIR 1.05; 95% CI 0.85‐1.29). PPI use, dose or duration of use was not associated with osteoporotic fracture risk (HR 0.87; 95% CI 0.12‐6.39). Independent risk factors for osteoporotic fractures included older age, female gender and higher co‐morbidity index.ConclusionsThe incidence of osteoporotic fractures was not increased in BO patients compared to the general population. In addition, PPI use was not associated with increased fracture risk regardless of the duration of therapy or dose.
Prediction of individual outcomes for asthma sufferers
Storlie, Curtis B. , Shah, Nilay D. , Rank, Matthew A. , Branda, Megan E. , Gionfriddo, Michael R.

Mayo Clinic

Biostatistics | October 4, 2017 | Volume: 19 | Issue: 4 | Pages: 579-593

10.1093/biostatistics/kxx055 | PMID 29121247 Get It

Direct Detection and Identification of Prosthetic Joint Pathogens in Synovial Fluid (SF) by Metagenomic Shotgun Sequencing
Ivy, Morgan I. , Thoendel, Matthew , Greenwood‐Quaintance, Kerryl E. , Hanssen, Arlen D. , Yao, Janet , Mandrekar, Jayawant N. , Jeraldo, Patricio , Abdel, Matthew P. , Chia, Nicholas , Tande, Aaron J. , Patel, Robin

Mayo Clinic

Open Forum Infectious Diseases | October 4, 2017 | Volume: 4 | Issue: suppl_1 | Pages: S32-S32

10.1093/ofid/ofx162.078 Get It

Abstract Background Detection and identification of microorganism(s) involved in periprosthetic joint infection (PJI) can inform surgical management and directed antibiotic therapy. Metagenomic shotgun sequencing is a powerful tool with the potential to change how many PJIs are diagnosed as it allows direct detection and identification of pathogens in clinical specimens. In the largest series to date, we utilized a metagenomics-based approach applied to SF to define potential microbial etiologies of failed total knee arthroplasties (TKAs). Methods Synovial fluid was collected from 112 failed TKAs [74 PJI and 38 aseptic implant failure (AF)] via preoperative arthrocentesis. Cell count and differential, standardized culture and DNA-based metagenomic shotgun sequencing were performed. Human DNA was depleted using the MolYsis basic kit prior to DNA extraction, whole genome amplification, and sequencing. Taxonomic assignment of reads and pathogen identification was achieved using a pipeline incorporating k-mer- and marker gene-based classification software. A scheme for analysis and filtration of false-positives was created and applied, incorporating cut-offs for the number of reads, quality scores, and coverage across a reference genome. Patients were classified as having PJI using the IDSA criteria and expert review. Analyses were recorded as percent agreement, with 95% confidence intervals (CI), of metagenomics to SF culture. Results Metagenomic analysis identified the known pathogen in 54 (90%) (CI, 79.5%–96.2%) of the 60 culture-positive PJIs analyzed and one (2%) (CI, 0.0%–8.9%) potential polymicrobial infection not detected by culture. For the 14 culture-negative PJIs tested, metagenomics showed 79% (CI, 49.2%–95.3%) agreement for negative findings; potential pathogens were identified in three (21%) (CI, 4.7%–50.8%) culture-negative PJI cases, with one being polymicrobial. Of the 37 culture-negative AF cases, metagenomics showed 97% (CI, 85.8%–99.9%) agreement with negative culture and identified one (3%) (CI, 0.0%–14.2%) potential pathogen. For the one culture-positive AF case, metagenomic results were negative, suggesting possible culture contamination. Conclusion Metagenomic shotgun sequencing performed on SF can be used to diagnose PJI and may be particularly useful for culture-negative PJI. Disclosures R. Patel, ASM: Board Member, None; CD Diagnostics, BioFire, Curetis, Merck, Hutchison Biofilm Medical Solutions, Accelerate Diagnostics, Allergan, and The Medicines Company: Grant Investigator, Grant recipient; Curetis: Consultant, Monies paid to my employer; A patent on Bordetella pertussis/parapertussis PCR issued, a patent on a device/method for sonication with royalties paid by Samsung to Mayo Clinic, and a patent on an anti-biofilm substance issued: Patents, Patents, any money is paid to my employer; Actelion: DSMB, Money paid to my employer; ASM and IDSA: Editor’s stipends, Editor’s stipends; NBME, Up-to-Date and the Infectious Diseases Board Review Course: NBME, Up-to-Date and the Infectious Diseases Board Review Course, Honoraria; Roche, ASM, and IDSA: Travel reimbursement, Travel reimbursement
Common TDP1 Polymorphisms in Relation to Survival among Small Cell Lung Cancer Patients: A Multicenter Study from the International Lung Cancer Consortium
Lohavanichbutr, Pawadee, Arnold, Susanne M. , Davies, Michael P.A. , Field, John K. , Haura, Eric B. , Hung, Rayjean J., Kohno, Takashi , Landi, Maria Teresa , Liu, Geoffrey , Marcus, Michael W. , O’Kane, Grainne M. , Schabath, Matthew B. , Slone, Stacey , Tardón, Adonina , Yoshida, Kazushi, Zong, Xuchen, Goodman, Gary E. , Chen, Chu , Hung, Rayjean J. , Hung, Rayjean J , Liu, Geoffrey , Field, John K , Tardón, Adonina , Davies, Michael P A , Schabath, Matthew B , Sakoda, Lori C. , Amos, Christopher I. , Christiani, David C. , Liu, Yi , Shiraishi, Kouya , Yang, Ping , Zhang, Ruyang , Weiss, Noel S , Arnold, Susanne M , O'Kane, Grainne M.

Mayo Clinic

Clinical Cancer Research | October 3, 2017 | Volume: 23 | Issue: 24 | Pages: 7550-7557

10.1158/1078-0432.ccr-17-1401 | PMID 28974547 Get It

Abstract Purpose: DNA topoisomerase inhibitors are commonly used for treating small-cell lung cancer (SCLC). Tyrosyl-DNA phosphodiesterase (TDP1) repairs DNA damage caused by this class of drugs and may therefore influence treatment outcome. In this study, we investigated whether common TDP1 single-nucleotide polymorphisms (SNP) are associated with overall survival among SCLC patients. Experimental Design: Two TDP1 SNPs (rs942190 and rs2401863) were analyzed in 890 patients from 10 studies in the International Lung Cancer Consortium (ILCCO). The Kaplan–Meier method and Cox regression analyses were used to evaluate genotype associations with overall mortality at 36 months postdiagnosis, adjusting for age, sex, race, and tumor stage. Results: Patients homozygous for the minor allele (GG) of rs942190 had poorer survival compared with those carrying AA alleles, with a HR of 1.36 [95% confidence interval (CI): 1.08–1.72, P = 0.01), but no association with survival was observed for patients carrying the AG genotype (HR = 1.04, 95% CI, 0.84–1.29, P = 0.72). For rs2401863, patients homozygous for the minor allele (CC) tended to have better survival than patients carrying AA alleles (HR = 0.79; 95% CI, 0.61–1.02, P = 0.07). Results from the Genotype Tissue Expression (GTEx) Project, the Encyclopedia of DNA Elements (ENCODE), and the ePOSSUM web application support the potential function of rs942190. Conclusions: We found the rs942190 GG genotype to be associated with relatively poor survival among SCLC patients. Further investigation is needed to confirm the result and to determine whether this genotype may be a predictive marker for treatment efficacy of DNA topoisomerase inhibitors. Clin Cancer Res; 23(24); 7550–7. ©2017 AACR.
Magnetic Resonance Imaging Appearance of Schwannomas from Head to Toe: A Pictorial Review
Crist, Jamie , Hodge, Jacob R, Frick, Matthew A., Leung, Fiona P., Hsu, Eugene, Gi, Ming Tye, Venkatesh, Sudhakar K. , Frick, Matthew, Venkatesh, Sudhakar K , Hodge, Jacob R.

Mayo Clinic

Journal of Clinical Imaging Science | October 3, 2017 | Volume: 7 | Issue: No issue available | Pages: 38

10.4103/jcis.jcis_40_17 | PMID 29114437 Get It

Schwannomas are benign soft-tissue tumors that arise from peripheral nerve sheaths throughout the body and are commonly encountered in patients with neurofibromatosis Type 2. The vast majority of schwannomas are benign, with rare cases of malignant transformation reported. In this pictorial review, we discuss the magnetic resonance imaging (MRI) appearance of schwannomas by demonstrating a collection of tumors from different parts of the body that exhibit similar MRI characteristics. We review strategies to distinguish schwannomas from malignant soft-tissue tumors while exploring the anatomic and histologic origins of these tumors to discuss how this correlates with their imaging findings. Familiarity with the MRI appearance of schwannomas can help aid in the differential diagnosis of soft-tissue masses, especially in unexpected locations.
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Campone, Mario , Sohn, Joohyuk , Paluch–Shimon, Shani , Huober, Jens , Park, In Hae , Trédan, Olivier , Chen, Shin‐Cheh , Manso, Luís , Freedman, Orit, Jaliffe, Georgina Garnica, Forrester, Tammy , Frenzel, Martin, Barriga, Susana , Bourayou, Nawel, Leo, Angelo Di , Toi, Masakazu , Paluch-Shimon, Shani, Freedman, Orit C, Garnica Jaliffe, Georgina, Smith, Ian C., Di Leo, Angelo, Hae Park, In , Di Leo, Angelo , Goetz, Matthew P. , Smith, Ian C., Manso Sanchez, Luis , Sohn, Joohyuk

Mayo Clinic

Journal of Clinical Oncology | October 2, 2017 | Volume: 35 | Issue: 32 | Pages: 3638-3646

10.1200/jco.2017.75.6155 | PMID 28968163 Get It

Purpose Abemaciclib, a cyclin-dependent kinase 4 and 6 inhibitor, demonstrated efficacy as monotherapy and in combination with fulvestrant in women with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer previously treated with endocrine therapy. Methods MONARCH 3 is a double-blind, randomized phase III study of abemaciclib or placebo plus a nonsteroidal aromatase inhibitor in 493 postmenopausal women with HR-positive, HER2-negative advanced breast cancer who had no prior systemic therapy in the advanced setting. Patients received abemaciclib or placebo (150 mg twice daily continuous schedule) plus either 1 mg anastrozole or 2.5 mg letrozole, daily. The primary objective was investigator-assessed progression-free survival. Secondary objectives included response evaluation and safety. A planned interim analysis occurred after 189 events. Results Median progression-free survival was significantly prolonged in the abemaciclib arm (hazard ratio, 0.54; 95% CI, 0.41 to 0.72; P = .000021; median: not reached in the abemaciclib arm, 14.7 months in the placebo arm). In patients with measurable disease, the objective response rate was 59% in the abemaciclib arm and 44% in the placebo arm ( P = .004). In the abemaciclib arm, diarrhea was the most frequent adverse effect (81.3%) but was mainly grade 1 (44.6%). Comparing abemaciclib and placebo, the most frequent grade 3 or 4 adverse events were neutropenia (21.1% v 1.2%), diarrhea (9.5% v 1.2%), and leukopenia (7.6% v 0.6%). Conclusion Abemaciclib plus a nonsteroidal aromatase inhibitor was effective as initial therapy, significantly improving progression-free survival and objective response rate and demonstrating a tolerable safety profile in women with HR-positive, HER2-negative advanced breast cancer.
Draft Genome Sequence of Methanobrevibacter smithii Isolate WWM1085, Obtained from a Human Stool Sample
Jennings, Matthew E. , Boardman, Lisa A., Metcalf, William W. , Chia, Nicholas , Metcalf, William W , Chia, Nicholas , Boardman, Lisa A.

Mayo Clinic

Genome Announcements | September 30, 2017 | Volume: 5 | Issue: 39 | Pages: No page available

10.1128/genomea.01055-17 | PMID 28963219 Get It

ABSTRACT Methanobrevibacter smithii is a common inhabitant of the human gut. Here, we present a draft genome sequence of M. smithii isolate WWM1085, obtained from a human stool sample. This sequence will improve our understanding of the genetic diversity of this human-associated methanogen.
Event‐free survival at 24 months captures central nervous system relapse of systemic diffuse large B‐cell lymphoma in the immunochemotherapy era
Thanarajasingam, Gita , Maurer, Matthew J. , Farooq, Umar , Johnston, Patrick B., Thompson, Carrie A. , Bennani, Nabila Nora, Ansell, Stephen M. , Porrata, Luis F. , Macon, William R. , Syrbu, Sergei , Link, Brian K. , Nowakowski, Grzegorz S. , Bennani, Nabila N, Maurer, Matthew , Link, Brian K , Farooq, Umar , Johnston, Patrick B. , Cerhan, James R. , Habermann, Thomas M. , Witzig, Thomas E. , Syrbu, Sergei

Mayo Clinic

British Journal of Haematology | September 29, 2017 | Volume: 183 | Issue: 1 | Pages: 149-152

10.1111/bjh.14922 | PMID 28961306 Get It